All news

Pfizer faces 2027 patent cliff as new drugs lag

Alpha Vantage · Trefis · · AI-summarised by FinFlash

Pfizer stock yields 5.8% as the company works to replace older drugs facing patent expirations. Management flagged loss of exclusivity for Ibrance, Xtandi and Eliquis as key 2027 factors, raising concern that patent losses could outpace new drug growth. Sales are holding steady and the dividend appears covered by free cash flow.

Read original source

PFE company analysis

Understand the context

Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.